Latest Insider Transactions at Shattuck Labs, Inc. (STTK)
This section provides a real-time view of insider transactions for Shattuck Labs, Inc. (STTK). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Shattuck Labs, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Shattuck Labs, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 04
2024
|
Redmile Group, LLC Director |
BUY
Other acquisition or disposition
|
Indirect |
1,026,888
+15.64%
|
$1,026,888
$1.25 P/Share
|
|
Dec 04
2024
|
Redmile Group, LLC Director |
SELL
Other acquisition or disposition
|
Indirect |
1,026,888
-18.54%
|
$1,026,888
$1.25 P/Share
|
|
Dec 04
2024
|
Redmile Group, LLC Director |
BUY
Open market or private purchase
|
Indirect |
133,371
+2.35%
|
$133,371
$1.25 P/Share
|
|
Dec 04
2024
|
Redmile Group, LLC Director |
SELL
Open market or private sale
|
Indirect |
133,371
-2.41%
|
$133,371
$1.25 P/Share
|
|
Oct 07
2024
|
Taylor Schreiber Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
36,500
+33.95%
|
$36,500
$1.21 P/Share
|
|
Jun 28
2024
|
Tyler Brous |
BUY
Open market or private purchase
|
Direct |
3,000
+1.24%
|
$9,000
$3.9 P/Share
|
|
Jun 27
2024
|
Tyler Brous |
BUY
Open market or private purchase
|
Direct |
5,416
+2.25%
|
$16,248
$3.89 P/Share
|
|
Jun 26
2024
|
Taylor Schreiber Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
14,400
+29.45%
|
$43,200
$3.47 P/Share
|
|
Jun 04
2024
|
Taylor Schreiber Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,050
+13.17%
|
$9,150
$3.57 P/Share
|
|
May 10
2024
|
Stephen Stout |
SELL
Payment of exercise price or tax liability
|
Direct |
967
-1.3%
|
$9,670
$10.42 P/Share
|
|
Mar 28
2024
|
Redmile Group, LLC Director |
SELL
Other acquisition or disposition
|
Indirect |
4,425
-0.08%
|
-
|
|
Mar 06
2024
|
Stephen Stout |
SELL
Open market or private sale
|
Direct |
16,004
-6.41%
|
$160,040
$10.53 P/Share
|
|
Mar 06
2024
|
Stephen Stout |
BUY
Exercise of conversion of derivative security
|
Direct |
11,109
+6.12%
|
$33,327
$3.54 P/Share
|
|
Jan 30
2024
|
Casi De Young Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,008
-2.19%
|
$18,072
$9.99 P/Share
|
|
Jan 30
2024
|
Abhinav A. Shukla Chief Technical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,290
-2.8%
|
$20,610
$9.99 P/Share
|
|
Jan 30
2024
|
Stephen Stout |
SELL
Payment of exercise price or tax liability
|
Direct |
593
-0.74%
|
$5,337
$9.99 P/Share
|
|
Jan 30
2024
|
Arundathy N. Pandite Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,920
-1.33%
|
$26,280
$9.99 P/Share
|
|
Jan 10
2024
|
Stephen Stout |
BUY
Grant, award, or other acquisition
|
Direct |
49,050
+38.03%
|
-
|
|
Jan 10
2024
|
Abhinav A. Shukla Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
33,425
+29.03%
|
-
|
|
Jan 10
2024
|
Andrew R Neill Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
25,000
-12.6%
|
$250,000
$10.0 P/Share
|
|
Jan 10
2024
|
Andrew R Neill Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,470
-1.23%
|
$24,700
$10.09 P/Share
|
|
Jan 10
2024
|
Andrew R Neill Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
56,500
+21.95%
|
-
|
|
Jan 10
2024
|
Casi De Young Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,583
-1.7%
|
$15,830
$10.09 P/Share
|
|
Jan 10
2024
|
Casi De Young Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
46,200
+33.17%
|
-
|
|
Jan 10
2024
|
Arundathy N. Pandite Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,987
-1.34%
|
$29,870
$10.09 P/Share
|
|
Jan 10
2024
|
Arundathy N. Pandite Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
46,475
+17.29%
|
-
|
|
May 10
2023
|
Stephen Stout |
BUY
Grant, award, or other acquisition
|
Direct |
15,900
+33.99%
|
-
|
|
Jan 25
2023
|
Abhinav A. Shukla Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,100
+35.66%
|
-
|
|
Jan 25
2023
|
Erin Ator Thomson General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
24,125
+18.95%
|
-
|
|
Jan 25
2023
|
Andrew R Neill Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
34,925
+19.47%
|
-
|
|
Jan 25
2023
|
Casi De Young Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
27,100
+36.63%
|
-
|
|
Jan 25
2023
|
Arundathy N. Pandite Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
37,875
+17.73%
|
-
|
|
Jan 10
2023
|
Abhinav A. Shukla Chief Technical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,933
-8.43%
|
$5,799
$3.03 P/Share
|
|
Jan 10
2023
|
Arundathy N. Pandite Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,987
-2.12%
|
$8,961
$3.03 P/Share
|
|
Jan 10
2023
|
Casi De Young Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,583
-7.41%
|
$4,749
$3.03 P/Share
|
|
Apr 26
2022
|
George Golumbeski |
BUY
Open market or private purchase
|
Direct |
28,330
+34.16%
|
$84,990
$3.63 P/Share
|
|
Apr 22
2022
|
George Golumbeski |
BUY
Open market or private purchase
|
Direct |
234
+0.88%
|
$702
$3.67 P/Share
|
|
Apr 21
2022
|
George Golumbeski |
BUY
Open market or private purchase
|
Direct |
26,049
+50.0%
|
$78,147
$3.69 P/Share
|
|
Jan 28
2022
|
Taylor Schreiber Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,926
+18.71%
|
$15,704
$4.67 P/Share
|
|
Jan 19
2022
|
Tyler Brous |
BUY
Open market or private purchase
|
Direct |
3,000
+1.29%
|
$18,000
$6.87 P/Share
|
|
Jan 18
2022
|
Tyler Brous |
BUY
Open market or private purchase
|
Direct |
2,500
+1.09%
|
$17,500
$7.01 P/Share
|
|
Jan 14
2022
|
Tyler Brous |
BUY
Open market or private purchase
|
Direct |
2,500
+1.1%
|
$17,500
$7.16 P/Share
|
|
Jan 12
2022
|
Erin Ator Thomson General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+11.23%
|
$20,000
$2.95 P/Share
|
|
Jan 10
2022
|
Erin Ator Thomson General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
22,825
+24.83%
|
-
|
|
Jan 10
2022
|
Andrew R Neill Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
33,325
+23.33%
|
-
|
|
Jan 10
2022
|
Arundathy N. Pandite Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
34,738
+19.78%
|
-
|
|
Jan 10
2022
|
Casi De Young Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,363
+50.0%
|
-
|
|
Nov 11
2021
|
Andrew R Neill Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+20.8%
|
$40,000
$2.95 P/Share
|
|
Nov 10
2021
|
Taylor Schreiber Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,926
+23.02%
|
$15,704
$4.67 P/Share
|
|
Oct 19
2021
|
Erin Ator Thomson General Counsel |
SELL
Open market or private sale
|
Direct |
33,000
-41.64%
|
$627,000
$19.5 P/Share
|